17:29 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

pSivida reports Phase III data for Durasert in posterior segment uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) reported additional data from a Phase III trial in 153 patients with chronic, non-infectious posterior segment uveitis showing that intravitreal Durasert significantly reduced the recurrence of uveitis in the study eye...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Financial News

Alimera Sciences financial update

Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga.  Business: Ophthalmic  Date announced: 2016-10-20  Note: Alimera secured an additional $10 million under an amended loan from Hercules Technology Growth Capital , bringing the total available under the loan...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Medidur fluocinolone acetonide intravitreal implant: Completed Phase III enrollment

pSivida completed enrollment of 150 patients in a double-blind, sham-controlled, Indian Phase III trial evaluating 0.18 mg intravitreal Medidur. The product uses the same micro-insert and corticosteroid as Iluvien fluocinolone acetonide intravitreal implant to treat...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Medidur fluocinolone acetonide intravitreal implant: Additional Phase III data

Additional data from a double-blind, international Phase III trial in 129 patients with recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis showed that 0.18 mg intravitreal Medidur led...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Financial News

Alimera Sciences financial update

Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga.   Business: Ophthalmic   Date announced: 2016-08-16   Note: Alimera raised $1.3 million through the sale of 900,000 shares at $1.40 to cover the overallotment from its Aug. 11...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Financial News

Alimera Sciences completes follow-on

Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga.   Business: Ophthalmic   Date completed: 2016-08-11   Type: Follow-on   Raised: $25.2 million   Shares: 18 million   Price: $1.40   Shares after offering: 63.8 million   Underwriters:...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

pSivida ophthalmic news

In July, pSivida said it plans to consolidate all R&D to its facility in Watertown. Subject to an employee consultation process required by U.K. law, pSivida plans to close its research facility in Malvern, U.K....
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Medidur fluocinolone acetonide intravitreal implant: Phase III data

Top-line data from a double-blind, international Phase III trial in 129 patients with recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis showed that 0.18 mg intravitreal Medidur met...
01:51 , Dec 23, 2015 |  BC Extra  |  Clinical News

pSivida rises on Phase III uveitis data

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.79 (21%) to $4.49 on NASDAQ on Tuesday after its Medidur fluocinolone acetonide intravitreal implant met the primary endpoint in a Phase III study to treat chronic, non-infectious posterior uveitis....